| 前收盘价格 | 14.59 |
| 成交量 | 96,842 |
| 预期市盈率 (P/E Forward) | 161.29 |
| 价格/销量 (P/S) | 4.57 |
| 股市价格/股市净资产 (P/B) | 42.03 |
| 52周波幅 |
| 营业毛利率 | -29.42% |
| 营业利益率 (TTM) | -22.85% |
| 稀释每股收益 (EPS TTM) | -0.820 |
| 季度收入增长率 (YOY) | 24.30% |
| 总债务/股东权益 (D/E MRQ) | 301.42% |
| 流动比率 (MRQ) | 6.63 |
| 营业现金流 (OCF TTM) | -17.90 M |
| 杠杆自由现金流 (LFCF TTM) | -9.89 M |
| 资产报酬率 (ROA TTM) | -11.52% |
| 股东权益报酬率 (ROE TTM) | -128.49% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | Neuropace, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | -1.5 |
| 价格波动 | -1.0 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | 0.5 |
| 平均 | 0.38 |
|
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Core |
| 内部持股比例 | 2.75% |
| 机构持股比例 | 86.29% |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| WILLIAMS PATRICK F. | - | 14.28 | -1,162 | -16,593 |
| 累积净数量 | -1,162 | |||
| 累积净值 ($) | -16,593 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 14.28 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| WILLIAMS PATRICK F. | 职员 | 20 Sep 2026 | 处理 (-) | 1,162 | 14.28 | 16,593 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合